679 Characterization of tumor specific CD8+ T cell responses in patients with recurrent/metastatic HPV16-positive head and neck cancer receiving HB-200 monotherapy as second or later line treatment in a phase 1 study
Alan L. Ho, Alexander T. Pearson, Siqing Fu, Marshall R. Posner, Douglas R. Adkins, Lisle M. Nabell, Jiaxin Niu, Debra L. Richardson, Rom S. Leidner, Ki Y. Chung, Douglas Laux, Jorge J. Nieva, Stuart J. Wong, Katerin Rojas, Ari J. Rosenberg, Minh Phan, Trisha Kaufmann, Christopher Plescia, Xiaoping Qing, Corinne Iacobucci, Ilian Tchakov, Kia Katchar, Klaus K. Orlinger, Katia Schlienger, David G. PfisterRegular2023 · DOI
Patients with recurrent or metastatic (R/M) human papillomavirus 16-positive (HPV16+) head and neck squamous cell carcinoma (HNSCC) face a challenging prognosis once standard first-line therapies, such as platinum-based chemotherapy or checkpoint inhibitors, have failed. While immunotherapy has transformed the landscape of oncology, many patients do not achieve durable responses due to low frequencies of tumor-specific T cells or an inability of those cells to infiltrate the tumor microenvironment.
HB-200 is a novel immunotherapy platform designed to address these limitations. It utilizes a heterologous "prime-boost" regimen of two replicating, attenuated arenavirus vectors—HB-201 (derived from lymphocytic choriomeningitis virus, LCMV) and HB-202 (derived from Pichinde virus, PICV). Both vectors are engineered to express a non-oncogenic HPV16 E7E6 fusion protein, aiming to generate a robust and targeted immune response against HPV-driven malignancies.
Methodology
This Phase 1 study (NCT04180215) evaluated HB-200 monotherapy in 41 patients with HPV16+ R/M HNSCC who had progressed after at least one prior systemic therapy. The treatment involved alternating intravenous administrations of HB-202 and HB-201 every three weeks (Q3W), transitioning to every six weeks (Q6W) thereafter.
The primary objectives included assessing safety and characterizing the circulating tumor-specific immune response. Researchers analyzed peripheral blood mononuclear cells (PBMCs) using direct IFN-γ ELISpot and intracellular cytokine staining (ICS). Notably, these assays were performed without prior in vitro expansion, providing a more accurate reflection of the patient's actual physiological immune state. Tumor biopsies were also analyzed to evaluate changes in the tumor microenvironment, and clinical activity was measured using RECIST v1.1 criteria.
The HB-200 Platform: Overcoming Vector Neutralization
A common hurdle in viral vector-based therapies is the development of anti-vector immunity. When the same virus is used repeatedly, the immune system may neutralize the vector before it can deliver its therapeutic payload. HB-200 bypasses this by alternating between LCMV and PICV. Because these are two distinct arenaviruses, the immune response generated against the first vector does not neutralize the second. This allows the "boost" phase to effectively focus the immune system's attention on the HPV16 E6/E7 antigens rather than the viral delivery vehicle itself.
Immunological Results
The study reported unprecedented levels of T cell expansion. Key findings included:
High Response Rate: HB-200 rapidly induced HPV16-specific CD8+ T cells in over 90% of the analyzed patients.
Magnitude of Expansion: Circulating tumor-specific T cells increased by a median of 174-fold from baseline, with some patients experiencing up to a 1250-fold increase. In the most dramatic cases, tumor-specific CD8+ T cells accounted for up to 48% of the total circulating CD8+ T cell population.
Durability: These responses were not transient; E6/E7-specific T cell levels were maintained for more than eight months and were ongoing at the time of the data cut-off.
Poly-functionality: Beyond sheer numbers, the induced T cells exhibited increased poly-functionality, meaning they were capable of producing multiple cytokines simultaneously, a trait associated with superior anti-tumor activity.
Clinical Efficacy and Tumor Infiltration
The massive systemic expansion of T cells translated into measurable clinical benefits and changes within the tumor microenvironment. Among 33 heavily pre-treated patients evaluable for imaging, the disease control rate (DCR) was 48.5%. This included one partial response and 15 patients with stable disease.
Analysis of paired tumor biopsies revealed that HB-200 successfully increased the infiltration of CD8+ T cells into the tumors. This is a critical milestone, as it demonstrates the therapy's ability to turn "cold" tumors (those lacking immune cell presence) into "hot" tumors, potentially making them more susceptible to further immune attack.
Conclusion
HB-200 monotherapy demonstrates a remarkable ability to induce and maintain high frequencies of tumor-specific CD8+ T cells in patients with advanced HPV16+ HNSCC. The magnitude of the T cell response—reaching nearly half of the total CD8+ population in some instances—is a significant advancement in cancer vaccinology.
While the monotherapy results are promising, the relatively low objective response rate suggests that the tumor microenvironment may still employ secondary immunosuppressive mechanisms to resist T cell attack. Consequently, future research will focus on combining HB-200 with checkpoint inhibitors to maximize clinical efficacy. By providing a massive "army" of T cells via HB-200 and removing the "brakes" of the immune system via PD-1/PD-L1 inhibition, this combination approach holds significant potential for patients with HPV-driven cancers.
Summary updated
Abstract
<h3>Background</h3> Prognosis is poor for patients with recurrent/metastatic (R/M) human papillomavirus (HPV) 16+ head and neck squamous cell carcinoma (HNSCC) after first-line standard of care therapy. HB-200 is comprised of an alternating sequence of two replicating attenuated arenavirus vectors derived from LCMV (HB-201) and Pichinde virus (HB-202), respectively, expressing the same non-oncogenic HPV16 E7E6 fusion protein.<sup>1</sup> In a Phase 1 study, HB-200 monotherapy induced strong and long-lasting HPV16 E6 and E7-specific CD8+ T cell responses and demonstrated a favorable safety profile and antitumor activity in previously treated patients with HPV16+ R/M HNSCC.<sup>2</sup> Here, we report long-term circulating tumor specific immune responses and clinical benefit in these patients. <h3>Methods</h3> Patients with HPV16+ HNSCC post at least 1 prior systemic R/M anti-cancer therapy were treated with HB-200 monotherapy (alternating intravenous administration of HB-202 and HB-201 every 3 weeks [Q3W] then Q6W) until disease progression or unacceptable toxicity. Four dose levels of HB-200 were explored. HPV16 specific T cell responses were evaluated in peripheral blood mononuclear cells (PBMCs) by both direct IFN-γ ELISpot and intracellular cytokine staining (ICS) performed without prior <i>in vitro</i> expansion. Tumor analyses including sequencing were performed for patients with available baseline and on-treatment biopsies. Antitumor activity was measured by RECIST v1.1 per investigator assessment. <h3>Results</h3> As of March 31, 2023, 41 patients with HPV16+ R/M HNSCC (37 oropharynx, 1 larynx, 2 nasopharynx, 1 unknown primary) were treated with HB-200 monotherapy. HB-200 rapidly induced HPV16+ tumor-specific CD8+ T cells in more than 90% of patients analyzed. The E6/E7 T cell responses were maintained for more than 8 months and on-going as of data cut-off. Circulating tumor-specific T cells responses increased up to 1250-fold (median 174, range 93–1250) from baseline, with more than 57% of patients exhibiting ≥1% (maximum 48%) tumor specific CD8+ T cells out of total CD8+ T cells. Furthermore, tumor-specific CD8+ T cells increased in poly-functionality during treatment. Characterization of paired tumor biopsies revealed that HB-200 induced increased CD8+ T cell infiltration in tumors. Across all HB-200 doses, disease control rate was 48.5% in 33 heavily pre-treated patients with imaging evaluation (1 partial response, 15 stable disease), and overall survival is being assessed. <h3>Conclusions</h3> HB-200 monotherapy induces promising HPV16+ tumor-specific T cell responses and tumor infiltration in heavily pre-treated patients. This immune response coupled with clinical benefit in monotherapy suggests that HB-200 may enhance and strengthen current immunotherapy approaches by targeting specific tumor antigens. <h3>Acknowledgements</h3> The authors would like to thank all the patients participating in this study, their caregivers and study personnel. The study is sponsored by Hookipa Pharma, Inc. <h3>Trial Registration</h3> Clinicaltrials.gov NCT04180215 <h3>References</h3> Lauterbach H, Schmidt S, Katchar K, Qing X, Iacobucci C, Hwang A, Schlienger K, Berka U, Raguz J, Ahmadi-Erber S, Schippers T, Stemeseder F, Pinschewer DD, Matushansky I, Orlinger KK. Development and Characterization of a Novel Non-Lytic Cancer Immunotherapy Using a Recombinant Arenavirus Vector Platform. <i>Front Oncol</i>. 2021 Oct 14;<b>11</b>:732166. doi:10.3389/fonc.2021.732166 Fu S, Nabell L, Pearson A, Leidner R, Adkins D, Posner M, Nieva JJ, Richardson DL, Pimentel A, Goel S, Wong SJ, Ho AL, Rosenberg A, Taylor MH, Abdul-Karim R, Iacobucci C, Qing X, Katchar K, Schlienger K, Pfister, DG. Recommended phase 2 dose (RP2D) of HB-200 arenavirus-based cancer immunotherapies in patients with HPV16+ cancers. <i>ASCO</i> 2022. Abstract 2517 <h3>Ethics Approval</h3> This study was approved by Ethics and Institutional Review Boards (IRBs) at all study sites. IRB reference numbers: 20–165A(5) (Memorial Sloan Kettering Cancer Center), IRB19–1294 (University of Chicago), 2019–0928 (University of Texas M. D. Anderson Cancer Center), HS# STUDY-19–01049 (Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute), 1275383 (Washington University School of Medicine), 1282128 (University of Alabama at Birmingham Heersink School of Medicine), 1266389 (Banner MD Anderson Cancer Center), H-200–001 (RM 662) (Stephenson Cancer Center at University of Oklahoma Health Sciences Center), STUDY2019000305 (Providence Cancer Institute), Pro00092499 (Greenville Hospital System University Medical Center), 202101073 (University of Iowa), HS-19–00931 (University of Southern California, Norris Cancer Center), PRO00036737 (Medical College of Wisconsin), CODIGO:EC/21/252/6495 (R) (Hospital Universitari Vall d’Hebron, Spain). All participants provided written informed consent.
BibTeX
@inproceedings{ho2023characterization,
author = {Alan L. Ho and Alexander T. Pearson and Siqing Fu and Marshall R. Posner and Douglas R. Adkins and Lisle M. Nabell and Jiaxin Niu and Debra L. Richardson and Rom S. Leidner and Ki Y. Chung and Douglas Laux and Jorge J. Nieva and Stuart J. Wong and Katerin Rojas and Ari J. Rosenberg and Minh Phan and Trisha Kaufmann and Christopher Plescia and Xiaoping Qing and Corinne Iacobucci and Ilian Tchakov and Kia Katchar and Klaus K. Orlinger and Katia Schlienger and David G. Pfister},
title = {{679 Characterization of tumor specific CD8+ T cell responses in patients with recurrent/metastatic HPV16-positive head and neck cancer receiving HB-200 monotherapy as second or later line treatment in a phase 1 study}},
booktitle = {Regular},
year = {2023},
doi = {10.1136/jitc-2023-sitc2023.0679},
}